众所周知,用来治疗糖尿病的药物罗格列酮(商品名文迪雅),在发现其可以增加心梗和心血管死亡风险后,终于在2010年从欧洲市场撤出,并在美国被严格限制应用。针对罗格列酮的争论已经持续了多年,在其退出历史舞台之前,美国食品药品监督管理局(FDA)早在2008年已经决议,以后针对新的2型糖尿病药物应该接受更为严格的临床试验,以排除心血管毒性,而不能只基于某些单纯证明待测药物 It is well-known that Rosiglitazone, a drug used to treat diabetes, (Avandia) is finally withdrawn from the European market in 2010 after it is found to increase the risk of MI and cardiovascular death and is severely restricted in the United States application. The controversy over rosiglitazone has been around for many years, before the United States Food and Drug Administration (FDA) decided in 2008 to withdraw from the historic arena and later on for new type 2 diabetes drugs should undergo more rigorous clinical Test to rule out cardiovascular toxicity, not just based on some simple proof test drug